ArticleJournal of molecular histology2026
lncRNA MEG3 and Beclin-1 as diagnostic biomarkers in serous ovarian carcinoma: molecular and immunohistochemical insights.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serous ovarian carcinoma (SOC) is frequently diagnosed at advanced stages and is associated with poor clinical outcomes, highlighting the urgent need for reliable diagnostic and prognostic biomarkers. Long non-coding RNA MEG3 and the autophagy-related protein Beclin-1 are recognized tumor suppressors; however, their combined diagnostic relevance in SOC remains insufficiently explored. This case-control study included 24 patients with histopathologically confirmed SOC. Paired tumor and adjacent non-tumorous ovarian tissues were analyzed for lncRNA MEG3 expression using quantitative real-time PCR and for Beclin-1 protein expression using immunohistochemistry. Serum CA-125 levels were assessed by ELISA. Associations with clinicopathological parameters were evaluated, and diagnostic performance was analyzed using receiver operating characteristic (ROC) curves. Both lncRNA MEG3 and Beclin-1 were significantly downregulated in SOC tissues compared with adjacent non-cancerous tissues (P < 0.0001). Reduced expression was significantly associated with tumor grade and ascites. The relationship with FIGO stage was not uniform in this cohort and should be interpreted cautiously because of the small sample size and unequal distribution of early and advanced cases. Beclin-1 expression was notably higher in premenopausal patients and in well to moderately differentiated tumors. A strong positive correlation was observed between lncRNA MEG3 and Beclin-1 expression (r = 0.96, P < 0.001), indicating a strong statistical association rather than a proven regulatory interaction. ROC curve analysis suggested diagnostic potential for lncRNA MEG3, Beclin-1, and serum CA-125. The concurrent downregulation of lncRNA MEG3 and Beclin-1 in SOC tissues suggests that these markers may serve as promising complementary biomarkers. However, their clinical utility should be considered preliminary and requires validation in larger, multicenter cohorts with functional studies before routine clinical application can be recommended.
Indexed as
Identifiers
42446766What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.